Shares of Apricus Biosciences Inc (NASDAQ:APRI) ended Friday session in red amid volatile trading. The shares closed down -0.048 points or -12.07% at $0.350 with 2.66 million shares getting traded. Post opening the session at $0.36, the shares hit an intraday low of $0.33 and an intraday high of $0.36 and the price vacillated in this range throughout the day. The company has a market cap of $20.40 million and the numbers of outstanding shares have been calculated to be 66.35 million shares.
Apricus Biosciences Inc (APRI) on Sept. 23, 2016 announced that it has entered into a definitive agreement with institutional investors for an offering of shares of common stock with gross proceeds of approximately $4.6 million in a registered direct offering. The closing of the offering is expected to take place on or about September 27, 2016, subject to the satisfaction of customary closing conditions.
In connection with the offering, the Company will issue approximately 13.1 million registered shares of common stock at a purchase price of $0.35 per share. Concurrently in a private placement, for each share of common stock purchased by an investor, such investor will receive from the Company an unregistered warrant to purchase 0.75 shares of common stock. The warrants have an exercise price of $0.45 per share, will be exercisable six (6) months following the closing date and will expire 5 years from the initial exercise date.
Shares of Hologic, Inc. (NASDAQ:HOLX) ended Friday session in red amid volatile trading. The shares closed down -0.33 points or -0.85% at $38.45 with 2.64 million shares getting traded. Post opening the session at $39.30, the shares hit an intraday low of $38.31 and an intraday high of $39.30 and the price vacillated in this range throughout the day. The company has a market cap of $10.58 billion and the numbers of outstanding shares have been calculated to be 277.42 million shares.
Hologic, Inc. (HOLX) on Sept. 8, 2016 announced that the U.S. Food and Drug Administration (FDA) has expanded the emergency use authorization (EUA) for the company’s Aptima® Zika virus diagnostic assay to be used with urine samples (collected alongside patient-matched serum or plasma specimens).
Hologic’s Zika virus assay was authorized for emergency use with serum and plasma (blood) samples in June 2016. Its new use with urine samples lengthens the time period during which patients can be tested for Zika from seven days to 14 days following symptoms, as recommended by the U.S. Centers for Disease Control and Prevention (CDC).
“This action by FDA is significant because it gives many more people the opportunity to be tested with our highly sensitive assay,” said Tom West, Division President of Diagnostic Solutions at Hologic. “In particular, this expanded indication allows us to better serve public health labs, increasing access to more people to detect and diagnose more disease.”